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Abstract
Background: Machine learning (ML) has emerged as a promising tool for risk stratifi-
cation. However, few studies have applied ML to risk assessment of patients with
atrial fibrillation (AF).
Hypothesis: We aimed to compare the performance of random forest (RF), logistic
regression (LR), and conventional risk schemes in predicting the outcomes of AF.
Methods: We analyzed data from 7406 nonvalvular AF patients (median age
71 years, female 29.2%) enrolled in a nationwide AF registry (J-RHYTHM Registry)
and who were followed for 2 years. The endpoints were thromboembolisms, major
bleeding, and all-cause mortality. Models were generated from potential predictors
using an RF model, stepwise LR model, and the thromboembolism (CHADS2 and
CHA2DS2-VASc) and major bleeding (HAS-BLED, ORBIT, and ATRIA) scores.
Results: For thromboembolisms, the C-statistic of the RF model was significantly
higher than that of the LR model (0.66 vs. 0.59, p = .03) or CHA2DS2-VASc score
(0.61, p < .01). For major bleeding, the C-statistic of RF was comparable to the LR
(0.69 vs. 0.66, p = .07) and outperformed the HAS-BLED (0.61, p < .01) and ATRIA
(0.62, p < .01) but not the ORBIT (0.67, p = .07). The C-statistic of RF for all-cause
mortality was comparable to the LR (0.78 vs. 0.79, p = .21). The calibration plot for
the RF model was more aligned with the observed events for major bleeding and all-
cause mortality.
Conclusions: The RF model performed as well as or better than the LR model or exis-
ting clinical risk scores for predicting clinical outcomes of AF.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common sustained arrhythmia seen
in the elderly population and is associated with an increased risk of
thromboembolisms, major bleeding, and mortality. 1 Treatment deci-
sions for AF are often made by risk prediction models built using a
regression analysis, but their accuracy is modest. 2–6 AF is a highly
heterogeneous condition caused by various underlying disorders, and
a simple risk score may limit the performance of the risk stratification. 7
Therefore, more accurate and personalized risk stratification approaches
are required.
Machine learning (ML), the use of mathematical algorithms that
address the higher dimensional, nonlinear relationships among many
variables, is making significant progress.8–10 Promising tools for ML in
cardiology include the improvement of the automated risk prediction
and interpretation of medical imaging that can have a dramatic impact
on the practice of cardiology. Currently, several studies have shown
that ML outperforms the risk prediction as compared to the traditional
logistic models. Mortazavi et al. showed an improved prediction of
readmissions for worsening heart failure with ML models as compared
to a logistic regression (LR) analysis.11 In another study using a large
multicenter database, the ML model was more accurate in detecting
clinical deterioration in the hospitalized patients than the traditional
regression models.12 In a more recent study using patients admitted
to the intensive care unit, Hyland et al. developed a new approach
that provides early identification of patients at risk for circulatory fail-
ure with a much lower false-alarm rate than conventional threshold-
based systems.13 However, contradictory results have also been
reported.14,15 While AF patients represent an important target popu-
lation for whom adverse events need predicting, few studies have
applied ML to the risk assessment in them. Therefore, the aim of this
study was to compare the discrimination and calibration performance
of an ML algorithm called the random forest (RF) model, against a
stepwise LR model and several conventional score based risk predic-
tors, to predict thromboembolisms, major bleeding, and all-cause mor-
tality, using a prospective nationwide registry of AF patients.16–18
2 | METHODS
2.1 | Patients
For this study, we used individual patient data from the J-RHYTHM
Registry.16–18 The J-RHYTHM Registry is an observational, prospec-
tive cohort study that enrolled patients with AF between January and
July of 2009 at 150 sites within Japan. In this post-hoc study, after
excluding patients with mitral stenosis or those who had undergone
mechanical valve replacements (n = 410), the final cohort included
7406 patients. Warfarin was used as an oral anticoagulation therapy
because no direct oral anticoagulants were available when this regis-
try was carried out. The study protocol conformed to the 1975 Decla-
ration of Helsinki and was approved by the Nippon Medical School
institutional review board and review board at each enrolling center.
All patients gave their written informed consent. The data that sup-
port the findings of this study are available from the corresponding
author upon reasonable request.
2.2 | Endpoints
The endpoint of thromboembolisms included ischemic strokes, tran-
sient ischemic attacks, and systemic embolisms. Major bleeding as the
safety endpoint included intracranial hemorrhage, gastrointestinal
bleeding, and other causes of bleeding requiring hospitalization. The
all-cause mortality was also tallied. The diagnostic criteria for each
event have been described in research design papers.16,17 The
patients were followed for 2 years, or until an endpoint, whichever
occurred first. All analyses of the rates of the endpoints were based
on the first event during follow-up. A local investigator ascertained
the events, and members of the outcomes review committee adjudi-
cated all outcomes.
2.3 | Risk scores
The components of the CHADS2
2 and CHA2DS2-VASc scores
3 for
thromboembolisms and the HAS-BLED,4 ORBIT,5 and ATRIA6 scores
for major bleeding are shown in the Supplementary file (Appendix S1).
In the CHA2DS2-VASc scores, we modified the “V” criterion to include
coronary artery disease only, because no data were available regarding
peripheral artery disease and aortic plaque. The time in therapeutic
range (TTR) was determined with the method of Rosendaal et al. 19 and
a labile international normalized ratio (INR) was defined as TTR < 60%.
For this determination, the target INR level was set at 1.6–2.6 for
patients aged 70 years or older and at 2.0–3.0 for patients aged youn-
ger than 70 years, in keeping with Japanese guidelines for AF pharma-
cotherapy.20 We assessed the predictive accuracy of the CHADS2 and
CHA2DS2-VASc scores for thromboembolisms and all-cause mortality
21
and the HAS-BLED, ORBIT, and ATRIA scores for major bleeding.
2.4 | Statistical analysis
The statistical analyses were performed with R project software
(R foundation, Vienna, Austria). An RF analysis was performed using the
Scikit-learn open-source ML library, version 0.21.2. In this study, we
used an RF algorithm, which is a decision tree-based ensemble learning
method for the classification, regression, and clustering of the data.22
The RF analysis was composed of three steps: (1) missing values impu-
tation, (2) classification model building, and (3) feature selection.
2.5 | Missing values imputation
There were 10 variables for which we did not have data from every
single patient. They were the height (13.8%), body weight (13.1%),
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hemoglobin (11.5%), platelet count (11.6%), creatinine (11.1%), total
cholesterol (25.5%), total bilirubin (29.5%), aspartate aminotransferase
(AST) (12.1%), alanine aminotransferase (ALT) (11.7%), and creatinine
clearance (11.1%). In cases with missing data, categorical variables
were replaced by the modes, and numerical variables were imputed
with sequential regression multivariate imputation.23
2.6 | Classification model building
The RF classifier was trained (80% of an overall cohort) and tested
(20%) on the feature-selected variables. After hyperparameter tuning
and feature selection on the training data, the model was fit to the
training data set. The predictive capacity of the models was estimated
by the mean value and 95% confidence interval of the C-statistic over
5-fold cross-validation. In this study, the RF model was fit using 1000
trees.
2.7 | Feature Selection
We used 42 variables in this study (Supplementary file, Appendix S2).
The feature selection on the training data was performed using a
sequential forward floating selection (SFFS).24 The SFFS is a family of
greedy search algorithms, which is used to select a subset of features
that is suitable for model building.
2.8 | Permutation importance
To provide a description of an individualized prediction made by the
algorithm, we measured the permutation importance on a testing
dataset.22,25 The permutation importance was calculated by measur-
ing how the performance of a classifier decreased when a single pre-
dictive variable was randomly shuffled. Because shuffling breaks the
association between the variable and target clinical outcome,
the resulting drop in performance of the classifier as measured by the
area under the curve (AUC) was indicative of how much the classifier
depended on the predictive variable.
2.9 | Stepwise LR analysis
We used the logit link function of R for stepwise multivariable LR. The
predictive capacity of the regression model was estimated via the
mean value and 95% confidence interval for the C-statistic over
the 5-fold cross-validation iterations.
2.10 | Model calibration
The performances of the RF and LR models were evaluated with cali-
bration plots comparing the expected and actual event rates for the
outcomes. The RF outputs were reconverted into posterior probabili-
ties by fitting the sigmoid functions.26 The risk of the outcomes was
calculated for each sub-interval bounded by the quintiles. A calibra-
tion slope smaller than one indicated an overestimation of the event
risks for that quintile. We also evaluated the relationship between the
existing clinical risk scores and the event rate. The existing risk scores
were presented as a continuous score or classified into three catego-
ries (low, intermediate, and high risk) based on previous literature.2–6
The high-risk event rate cutoff value was defined as the maximum
event rate (mean value of the highest quintile interval) in the calibra-
tion curve of the RF model. We calculated the net reclassification
improvement (NRI) by the NRI index and 95% confidence interval to
assess the added value of the LR model or risk scores compared
to the RF model.27 A continuous NRI was used to compare the RF
and LR, and a categorical NRI was used to compare the RF model and
existing risk scores.2–6 The baseline variables are presented as the
number and frequency or mean ± SD values, or the median and inter-
quartile range. The DeLong test was used to compare the C-statistics-
between the models.28 A two-tailed p value of <.05 was considered
significant.
3 | RESULTS
The baseline characteristics of the patients are shown in Table 1. We
analyzed 7406 patients with nonvalvular AF (age 69.8 ± 10.0 years,
female 29.2%). A total of 6404 patients (86.5%) were taking warfarin.
The prevalence of a previous stroke or transient ischemic attack, or
major bleeding were 13.8% and 4.5%, respectively. Supplemental
Table S2 shows the number of patients with the thromboembolism risk
scores and major bleeding risk scores divided into three categories.
3.1 | Model performance
Figure 1 compares the performance of the two models and various
scoring systems in predicting the three types of outcomes. During a
2-year follow-up, 126 patients (1.6%) had thromboembolisms,
140 (1.8%) had major bleeding, and 195 (2.6%) died. The C-statistic of
the RF model for predicting thromboembolisms was 0.66 (95% CI
0.62–0.70), which was significantly higher than that of the LR model
(0.59, p = .03) and CHA2DS2-VASc score (0.61, p < .01) but was mar-
ginally higher than that of the CHADS2 score (0.62, p = .05). For
major bleeding, the C-statistic of the RF model (0.69, 95% CI 0.66–
0.72) was comparable to that of the LR model (0.66, p = .07). The C-
statistic of the RF model outperformed the HAS-BLED (0.61, p < .01)
and ATRIA (0.62, p < .01), but not the ORBIT (0.67, p = .07). For the
all-cause mortality, no significant difference was observed in the C-
statistic between the RF model (0.78, 95% CI 0.75–0.82) and LR
model (0.79, 95% CI 0.77–0.82). The discriminatory power of the RF
model outperformed the CHADS2 score (0.68, p < .001) and
CHA2DS2-VASc score (0.70, p < .01) for predicting the 2-year all-
cause mortality.
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3.2 | Permutation importance of the RF model
The features in the order of the permutation importance of the RF
model for predicting the three types of outcomes are shown in
Figure 2. For thromboembolisms, in addition to previously known risk
factors such as the age, systolic blood pressure, strokes, creatinine,
and body weight, three new factors, the total cholesterol, height, and
hepatic enzymes, were found to contribute to improving the model
performance (Figure 2(A)). For major bleeding, the most predictive
patient features in the order of a decreasing contribution included the
age, creatinine clearance, and a history of any bleeding (Figure 2(B)).
For the total mortality, creatinine clearance, age, and congestive heart
failure were the three main features (Figure 2(C)). The permutation
importance of risk factors in the LR model is shown in the Supplemen-
tary file (Figure S1).
3.3 | Independent predictors of the stepwise
LR model
The independent predictors of the three types of outcomes found by
the LR model are shown in Figure 3. Of the nine predictors found, the
labile INR, height, body weight, age, and strokes were predictors com-
mon to the LR and RF models, but the type of AF and use of calcium
channel blockers and beta-blockers, were not picked up by the RF
model (Figure 3(A)). For major bleeding, the independent predictors in
the LR model not picked up by the RF model were the body weight
and AF type (Figure 3(B)). For all-cause mortality, the total cholesterol,
ALT, and diastolic blood pressure were independent predictors not
picked up by the RF model (Figure 3(C)).
TABLE 1 Baseline characteristics of the patients
Overall
(n = 7406)
Age, years 69.8 ± 10.0
71 [64–77]
Age ≥ 75 years 2565 (34.6)
Male, (n) % 5241 (70.8)
Height (cm) 162 ± 9.1
Weight (kg) 62.2 ± 12.2
Systolic blood pressure (mmHg) 126.0 ± 16.2
Diastolic blood pressure (mmHg) 73.5 ± 17.0
Heart rate (beat per min) 72.5 ± 13.2





Congestive heart failure 2055 (27.7)
Hypertension 4481 (60.5)
Diabetes 1359 (18.3)
Previous stroke or TIA 1022 (13.8)




Congenital heart disease 96 (1.3)
Hyperthyroidism 131 (1.8)
Abnormal renal or liver function 901 (12.2)
Alcohol use >8 U/week 2263 (30.6)
Labile INR 3330 (44.9)
History of hepatitis 316 (4.3)
Previous bleeding, n (%)
Intracranial 81 (1.1)
Gastrointestinal 170 (2.3)
Other sites 78 (1.1)
Laboratory data
Hemoglobin (g/dl) 13.7 ± 1.7
Platelet (104/ul) 23.3 ± 25.7
Creatinine (mg/dl) 0.96 ± 0.56
CCr (ml/min) 68.5 ± 26.6
Total cholesterol (mg/dl) 188.8 ± 36.7
Total bilirubin (mg/dl) 0.82 ± 2.5
AST (IU/L) 26.1 ± 10.9
ALT (IU/L) 22.6 ± 13.1
Medications, n (%)
Warfarin 6404 (86.5)
Antiplatelet agents 1937 (26.2)
Antihypertensive drugs 5354 (72.2)
Class I Antiarrhythmic drug 1248 (16.9)
TABLE 1 (Continued)
Laboratory data






Note: Data represent number, frequency, or means ± SD.
Abbreviations: Abnormal liver function, chronic hepatic disease or
significant hepatic derangement (e. g., bilirubin >2 upper limit of normal,
in association with aspartate aminotransferase/alanine aminotransferase/
alkaline phosphatase >3 upper limit normal); Abnormal renal function,
chronic dialysis, renal transplantation, or serum creatinine >2.26 mg/dl;
ACE, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ALT,
alanine aminotransferase; Antihypertensive drugs include α-blocker,
dihydropyridine calcium channel blocker, and diuretics; ARB, angiotensin II
type 1 receptor blocker; AST, aspartate aminotransferase; CCB,
nondihydropyridine calcium channel blocker; CCr, creatinine clearance;
COPD, chronic obstructive pulmonary disease; INR, international
normalized ratio of prothrombin time; labile INR, therapeutic time in
range < 60%; TIA, transient ischemic attack.
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3.4 | Model calibration
In Figure 4, the continuous calibration plots for the RF and LR
models, and categorical calibration of the risk scores are pres-
ented. With regard to thromboembolisms (Panels A  C), both the
RF and LR models overestimated the actual observed event rate in
the high-risk (>3.0%) population, and the LR model under-
estimated the event rate in the lower risk population. The
CHADS2 and CHA2DS2-VASc scores underestimated the event
rates for the high-risk population. With regard to the major bleed-
ing (Panels D  F), the calibration plot for the RF model approxi-
mated the observed event rate. The LR model overestimated the
event rate in the high-risk (>4.1%) population. The ORBIT score
estimated the high-risk population well. With regard to the all-
cause mortality (Panels G  I), the RF model showed good agree-
ment between the estimated and observed event rates, while the
LR model overestimated the event rate in the high-risk (>7.8%)
population. The CHADS2 and CHA2DS2-VASc scores under-
estimated the event rates in the high-risk population. The calibra-
tion plots for the continuous risk scores are presented in the
Supplementary file (Figure S2).
3.5 | Net reclassification improvement
The NRI for the outcomes between the models are presented in Sup-
plemental Table S3. For thromboembolisms, the RF model more cor-
rectly identified events than the LR model and CHA2DS2-VASc score.
For major bleeding, the RF model showed no significant improvement
in the discriminatory ability over the LR model or risk scores. For the
all-cause mortality, the RF model was no better than the LR model but
was better than the CHADS2 and CHA2DS2-VASc scores.
4 | DISCUSSION
In this study, we compared the accuracy of the RF model, against the
LR model and existing clinical risk scores for predicting three types of
clinical outcomes of AF, namely, thromboembolisms, bleeding, and
mortality, using a nationwide AF registry. The predictive performance
of the RF model for thromboembolisms was modest but significantly
outperformed the LR model and CHA2DS2-VASc score. For major
bleeding and all-cause mortality, the predictive performance of the RF
model was modest and comparable to the LR model, while it had a







































F IGURE 1 C-statistics of the outcomes. The receiver operating characteristic curves for (A) thromboembolisms, (B) major bleeding, and
(C) all-cause mortality are shown in the upper figures. The C-statistic and 95% confidence intervals are presented in the lower table. The C-
statistics of the RF were compared to that for the LR and clinical risk scores. RF: random forest, LR: stepwise logistic regression. The other
abbreviations of the risk scores are shown in the supplementary file. Compared to RF: * <0.05, † < 0.01, # <0.001
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History of intracranial bleeding
Creatinine
Labile INR























Mean decrease in AUC
(A) Thromboembolism
(B) Major bleeding 
(C) All-cause mortality
F IGURE 2 Permutation importance of the random forest model. Permutation importance for the classification of (A) thromboembolisms,
(B) major bleeding, and (C) all-cause mortality. The mean decrease in the AUC is a measure of the permutation importance. It shows how much a
prediction made by the random forest model is degraded if a particular variable is shuffled (effectively removed). By inference, a variable with a
larger decrease in the AUC must be contributing more to the model's predictive ability. AUC: area under the curve. The definitions of abnormal
renal or hepatic function and other abbreviations are as in Table 1
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superior discrimination ability as compared to several risk scores. Our
study suggests that the RF model performs as well as, or better than
the LR model and conventional risk scores for predicting clinical out-
comes in AF patients.
Despite the claims that ML models outperform conventional
regression models in clinical medicine, few studies have compared the
predictive performance between ML models and the LR model or
existing risk scores in AF patients. Recently, Loring et al.15 examined
F IGURE 3 Independent predictors of the stepwise logistic regression model. The independent predictors and their odds ratio and 95%
confidence interval of (A) thromboembolisms, (B) major bleeding, and (C) all-cause mortality are shown. The definitions of abnormal renal or
hepatic function and other abbreviations are as in Table 1
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the performance of three ML approaches (RF, gradient boosting, and
neural networks) and the LR model in predicting strokes, major
bleeding, and mortality, using two global AF registries (ORBIT-AF
and GARFIELD-AF). The cross-registry validation revealed that the
LR model had a similar or better discrimination and calibration per-
formance for these three outcomes compared to ML. They also
reported the superiority of gradient boosting among the ML models.
In our study, we showed that the discriminatory power of the RF
model was highest for death (C-statistic = 0.78) and lowest for
thromboembolisms (C-statistic = 0.66). These C-statistic values
were comparable to the abovementioned study by Loring et al.,
where the highest C-statistic in the LR was for death (C-statis-
tic = 0.80 in ORBIT-AF, 0.75 in GARFIELD-AF) and the lowest
C-statistic was for strokes (C-statistic = 0.67 in ORBIT-AF, 0.66 in
GARFIELD-AF).15 In addition, the C-statistic for major bleeding in
the RF model in our study was 0.69, which was comparable to that
of the LR model by Loring et al. (C-statistic = 0.71 in ORBIT-AF,
0.64 in GARFIELD-AF). Our study examined the consistency of indi-
vidual risk predictions between models to assess their usefulness in
identifying patients at high risk. We found that the LR model under-
estimated the low risks and overestimated the high risks for throm-
boembolisms, probably due to overfitting. This pattern was repeated
for major bleeding and mortality. The RF model, however, predicted
major bleeding and mortality well. This observation was contrary to
that of Loring et al., who found a well aligned calibration in the LR
models. The cause of this difference is unknown, but many factors
can play a role, such as the sample size, number of parameters con-
sidered, rate of missing data, patient race, drugs used (warfarin or
F IGURE 4 Calibration plots. The plots comparing the predicted event rates (horizontal axis) and observed event rates (vertical axis) for
thromboembolisms (A, B, C), major bleeding (D, E, F), and all-cause mortality (G, H, I) are shown. The blue line in the RF and LR indicates the trend
for the calibration. When the intersect of the observed and expected event rates is below the dotted line, this indicates an overestimation of the
event risks for that quintile. (C, F, I) The plots comparing the categorical score (horizontal axis) and observed event rates (vertical axis) are shown.
The high-risk event rate cutoff values were 3.0%, 4.1%, and 7.8% for thromboembolisms, major bleeding, and all-cause mortality, respectively (red
shaded area). The abbreviations and categorical grouping are shown in Table 1 and the Supplementary File (Appendix S1 and Table S1).
RF: random forest, LR: stepwise logistic regression
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direct oral anticoagulants), comorbidities, treatment or survival rate,
number of censors,14 and tuning of the model hyperparameters.
ML models are often thought of as black boxes that take input
and produce output. Interactions between the features and intermedi-
ate steps that affect output are poorly understood. The algorithm of
the RF model is also a black box, but has the advantage of revealing
factors (permutation importance) that contribute to improving the
accuracy of the model and discovering complex interactions, even in
high-dimensional environments.25 At a high level, it works by ran-
domly shuffling data for one feature at a time over the entire data set
and calculating how much the performance metric of interest drops.
Although the permutation importance is heuristic, it can correct the
feature importance bias. To calculate the permutation importance,
the number of permutations does not grow exponentially and is pro-
portional to the number of the parameters. In this study, for example,
the RF model selected the total cholesterol, height, hepatic enzymes,
and labile INR for the risk estimation of thromboembolisms. Those
variables have not been reported previously and are not considered in
the LR model or existing risk scores. The LR model is often limited for
data mining purposes because of interactions of multiple, nonlinear
variables. The RF analysis, however, uses a nonparametric decision
tree approach to overcome these issues. In other words, the risk fac-
tors selected by the RF model and not by the LR were such that the
increase in their values was not related to a monotonic increase or
decrease in the risk.
In this study, the RF model significantly improved the prediction
of the outcomes when compared to the LR and standard clinical risk
scores. Our approach used variables that are typically measured clin-
ically. Although our understanding of the risk factors that regulate
the risk of AF patients is based on clinical observation, there is lim-
ited information on the underlying mechanisms. Therefore, we sup-
posed that the incorporation of the underlying mechanisms, such as
the inflammatory cytokines,29 autonomic balance,30 atrial imaging
parameters,31 or multiomics approaches32 may enable a more
sophisticated risk stratification scheme. In addition to the above-
mentioned parameters, incorporation of population-based risk fac-
tors such as the race/ethnicity, smoking, education, marital status,
home ownership, and physical activity may further improve the pre-
dictive accuracy. Another advantage of RF is that we can describe
the effect of each variable on an individualized prediction. Lack of
interpretability of the novel features or patterns, however, raises
some important questions for the clinician. We need to maximize
both the accuracy and interpretability of the ML, but so far there is
a trade-off between the two. Currently, ML has limited clinical appli-
cation for a risk assessment, but it could be utilized to personalize
the risk assessment when programmed algorithms are implemented
in electronic health records. We expect that ML will automatically
collect variables and integrate all relevant clinical risk measurements
to calculate the risk scores. Such a diagnostic support or computer-
ized alerts may provide timely information that may improve the
clinical decisions and potentially enhancing the therapeutic strate-
gies. The prediction accuracy based on ML models depends on fac-
tors such as the data heterogeneity, ML choices, and feature
selection algorithms. To test the clinical significance of our model,
we need to validate them in multicenter datasets, clinical trials, and
computational experiments.
4.1 | Study limitations
This study had many strengths, including the large number of sites
and patients studied and high quality of the clinical data collected
through the registry, but had some limitations. The J-Rhythm Reg-
istry was limited to cardiology practices that actively volunteered
to participate in this nationwide registry and was not a randomized
or blinded study. In this study, 86.5% of the patients were on anti-
coagulants, which may have confounded the models for the pre-
diction of thromboembolisms and major bleeding. Additionally, no
direct oral anticoagulants were used. This study was conducted
with patients of Asian race only, therefore outcomes may differ in
other races. Although the event rates for the three endpoints were
very low (6.2%), we did not consider the class imbalance. To
address this problem, we should apply a technique such as syn-
thetic minority over-sampling technique to achieve better classi-
fier performance.33 In this study we used the RF model and did not
employ support vector machine and neural network. The advan-
tage of RF over the support vector machine and neural network is
that RF works well for data analyses with a mixture of categorical
and continuous values. In the future study, other types of ML algo-
rithms should be tried.
5 | CONCLUSIONS
Our study showed that the RF model performed as well as or better
than the LR model or existing risk scoring schemes for predicting clini-
cal outcomes. The RF model was also able to provide information on
the relative importance of individual risk factors. The RF model has
the potential to be implemented clinically and improve the decision
making in patients with AF.
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